A phase I/II study of regorafenib (R) plus avelumab (A) in digestive tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps3125
Abstract: TPS3125Background: Several preclinical studies have shown that simultaneous blockade of programmed death(PD) 1/PD-L1 and neoangiogenesis induces synergistic anti-tumour effect in vivo. R is a multi... read more here.
Keywords: study regorafenib; avelumab digestive; digestive tumors; regorafenib plus ... See more keywords